Vor Ort
Merkzettel Warenkorb
  • Produktbild: The Evaluation of Beat Blocker and Calcium Antagonist Drugs
  • Produktbild: The Evaluation of Beat Blocker and Calcium Antagonist Drugs
Band 18

The Evaluation of Beat Blocker and Calcium Antagonist Drugs

Aus der Reihe Developments in Cardiovascular Medicine

49,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

02.11.2011

Herausgeber

J. Morganroth + weitere

Verlag

Springer Netherland

Seitenzahl

419

Maße (L/B/H)

23,5/15,5/2,3 cm

Gewicht

639 g

Auflage

Softcover reprint of the original 1st ed. 1982

Sprache

Englisch

ISBN

978-94-009-7563-7

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

02.11.2011

Herausgeber

Verlag

Springer Netherland

Seitenzahl

419

Maße (L/B/H)

23,5/15,5/2,3 cm

Gewicht

639 g

Auflage

Softcover reprint of the original 1st ed. 1982

Sprache

Englisch

ISBN

978-94-009-7563-7

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: The Evaluation of Beat Blocker and Calcium Antagonist Drugs
  • Produktbild: The Evaluation of Beat Blocker and Calcium Antagonist Drugs
  • Beta-Adrenoceptor Blocking Agents: Historical Perspectives.- The Clinical Relevance of Beta-Receptor Blockade, Intrinsic Sympathomimetic Activity and Membrane Depressant Action.- Pharmacokinetics and Pharmacodynamics of Beta Blockers.- Importance of Alpha Blocking and Vasodilator Effects of Beta Blocking Agents.- Are Animal Models Useful in Determining if All Beta-Blocking Agents Are the Same.- Moderator’s Comments on Beta Blocking Drugs.- General Group Discussion: Are All Beta Blocking Agents the same.- How to Define Beta Blocker Usefulness in Hypertension Is Ambulatory Monitoring Necessary.- Evaluation of Beta Blocking Agents in the Treatment of Angina Pectoris Due to Coronary Artery Disease.- Beta Blocking Agents in the Treatment of Ventricular Arrhythmias.- How to Define Beta Blocker Usefulness in Supraventricular Arrhythmias.- How to Define Beta Blocker Usefulness in Hypertension, Angina and Arrhythmias: An Overview.- General Group Discussion: How to Define Beta Blocker Usefulness.- Comparative Safety of Beta Blocking Drugs.- Current Problems in the Evaluation of New Beta Blocking Agents.- General Group Discussion: Problems in Study Design.- Remarks by Commissioner of Food and Drugs.- Beta Blocker in Sudden Death Prevention.- Do Beta-Blockers Prolong Life.- Clinical Trials to Prevent Sudden Death: what Are the Problems in Study Design.- Who Should Fund Clinical Trials.- General Group Discussion: Beta Blockers in Sudden Death Prevention.- Calcium Channel Blockers/Historical Perspectives.- Comparative Clinical Pharmacology of Slow Channel Blocking Agents.- The Electrophysiologic Differences of Calcium Antagonist Drugs.- Clinical Differences Between the Calcium Channel Blocking Agents.- General Group Discussion: Calcium Antagonists.- How to Define Controlled Studies in Coronary Artery Spasm.- Calcium Entry Blocking Agents: How to Define Controlled Studies in Patients with Arrhythmias.- Evaluation of Beta Blockers and Calcium Antagonists in the Treatment of Hypertrophic Cardiomyopathy.- Determination of the Safety of Calcium Antagonists in Combination with Beta-Adrenergic Blocking Agents — the Case for Circumscribed Clinical Trials.- General Group Discussion: How to Define Controlled Studies.- List of Participants.